Boston, MA (PRWEB) January 29, 2015 Dr. James Sherley, Director of the new biotech start-up Asymmetrex, LLC (formerly known as The Adult Stem Cell Technology Center, LLC) is looking forward to four upcoming opportunities in 2015 to continue to impress both academic and industry audiences with his companys very frank take on what is needed to accelerate progress in stem cell medicine. Asymmetrex has set the focus for its efforts on adult stem cells that are found in the organs and tissues of children and adults. Unlike human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), adult stem cells are free of induced mutations, are not tumor-forming, and have the essential ability to continuously regenerate mature human tissue cells like those in children and adults. To date, hESCs and iPSCs have only been able to regenerate immature cells, and even those not continuously. Previously, the two main challenges hindering wider use of adult stem cells for drug development and medical therapies have been difficulty producing them and difficulty counting them. Asymmetrex has reported, and in many cases secured patents for, new technologies that reduce or eliminate both of these challenges. At the coming conferences, Dr. Sherley will describe … Continue reading →

MIAMI (PRWEB) January 29, 2015 Regenestem Network, the worlds largest membership network of regenerative medicine practitioners, has announced the launch of a new stem cell clinic in Oaxaca, Mexico. The new facility, offering the most advanced cellular medicine protocols and techniques available is in partnership with Ulises Cervera, M.D. a neurologist coming from the Children's Hospital of Morelia, Mexico. The new Oaxaca facility will offer the most advanced protocols and techniques available in stem cell medicine to patients from across Mexico and around the world. Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner. In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries. Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies. Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services … Continue reading →

Stem Cell Therapy + PRP Helps Shoulder Injury and Whiplash Patient - Denise Lawson Denise Lawson experienced two motor vehicle accidents in 2001 that left her with neck pain, headaches, and sporadic episodes of weakness on the left side of her body. Over time, Denise developed... By: StemCell ARTS … Continue reading →

Rev Diabet Stud. 2009 Winter; 6(4): 260270. 1Tissue Engineering and Banking Laboratory, National Center for Cell Science, Ganeshkhind Road, Pune MH 411007, India 2Division of Animal Sciences, Agharkar Research Institute, Agarkar Road, Pune, MH 411004, India 3Stem Cells and Diabetes Section, National Center for Cell Science, Ganeshkhind Road, Pune MH 411007, India 4Stempeutics Research Pvt. Ltd., 9th Floor, Manipal Hospital, HAL Airport Road, Bangalore 560017, India Received October 2, 2009; Revised December 5, 2009; Accepted December 11, 2009. Cellular microenvironment is known to play a critical role in the maintenance of human bone marrow-derived mesenchymal stem cells (BM-MSCs). It was uncertain whether BM-MSCs obtained from a 'diabetic milieu' (dBM-MSCs) offer the same regenerative potential as those obtained from healthy (non-diabetic) individuals (hBM-MSCs). To investigate the effect of diabetic microenvironment on human BM-MSCs, we isolated and characterized these cells from diabetic patients (dBM-MSCs). We found that dBM-MSCs expressed mesenchymal markers such as vimentin, smooth muscle actin, nestin, fibronectin, CD29, CD44, CD73, CD90, and CD105. These cells also exhibited multilineage differentiation potential, as evident from the generation of adipocytes, osteocytes, and chondrocytes when exposed to lineage specific differentiation media. Although the cells were similar to hBM-MSCs, 6% (3/54) of dBM-MSCs expressed proinsulin/C-peptide. … Continue reading →

Joanne Schnurr, CTV Ottawa Published Thursday, January 29, 2015 12:57PM EST Last Updated Thursday, January 29, 2015 7:07PM EST People with Multiple Sclerosis are holding out great hope tonight over clinical trials that will begin right here in Ottawa. It's part of an international study into special stem cells that have the ability to repair damage. There has been much talk before about stem cells and their therapeutic potential. This research goes beyond that, looking at the possibility that these particular mesenchymal stem cells might be able to fix nerves ravaged by MS. For people like 60-year-old Margo Murchison, it is a ray of hope in a bleak future living with her disease that has now become chronic. Id like to live a life like everybody else, says Murchison, be free to do whatever I want and help other people instead of relying on them to help me. Murchison was 27 years old, a French Immersion teacher, when she was first diagnosed with Multiple Sclerosis, a disabling disease of the central nervous system. She has since lost the use of her legs, her eyesight on two occasions and now one hand. But her mind is crisp and clear and full … Continue reading →